Novo Nordisk ( NYSE:NVO) and Eli Lilly ( NYSE:LLY) are making headlines againthis time, for potential benefits beyond weight ...

The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...

GLP-1 agents "have an intricate web of various effects," Al-Aly said in a press briefing. For example, the analysis showed ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions ...

SAN FRANCISCO, CA / ACCESS Newswire / January 21, 2025 / Gala introduces a groundbreaking digital health platform that ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, ...

McDonald's shares underperformed in 2024, likely due to the rise of GLP-1 medications. Learn why MCD stock is a Sell.

This is just a glimpse of the GLP-1 trends available to CivicScience clients. Want to see the full picture? Let’s talk.